Dosing & Uses
Dosage Forms & Strengths
Routine vaccination not recommended for adults (18 years or older) residing in the US; however, unimmunized or incompletely immunized adults exposed to wild poliovirus should be vaccinated with a 3-dose series
0.5 mL SC/IM 2 doses 1-2 months apart with 3rd dose 6-12 months later, OR
3 doses >1 months apart or enough to complete total 3 doses
Completely vaccinated adults can receive 1 booster dose if traveling to polio endemic areas or to areas where the risk of exposure is high
Risk of exposure to wild polioviruses
- Travelers to regions or countries where poliomyelitis is endemic or epidemic
- Healthcare workers in close contact with patients who may be excreting polioviruses
- Laboratory workers handling specimens that may contain polioviruses
- Members of communities or specific population groups with disease caused by wild polioviruses
Up-to-date vaccination schedules available at www.cdc.gov/nip/publications
<6 weeks old: Safety and efficacy not established
0.5 mL SC/IM; 2 doses 1-2 months apart (at 2 and 4 months old), 3rd dose 18 months later; and 4th dose at age 4-6 years old before entering school
Serious - Use Alternative
Significant - Monitor Closely
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
Fever >39 degrees C (38%)
Injection site tenderness (29%)
Injection site pain (13%)
Injection site swelling (11%)
Erythema at inj site (3%), induration (1%)
Hypersensitivity to neomycin, streptomycin, polymixin B
Defer if acute febrile illness
Do not administer additional doses if anaphylaxis to previous dose
Immunosuppressed patients may not develop immunity
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Inactivated virus of 3 strains; elicits antibody response following immunization
These products convey active immunity via stimulation of production of endogenously produced antibodies
The onset of protection from disease is relatively slow, but duration is long lasting (years)
Duration: Not established
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs